Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.…
All You Need to Know About Outset Medical (OM) Rating Upgrade to Buy
Outset Medical (NASDAQ: OM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 310 employees.
The shares were at 2.810 USD on 20 November 2026, down 76.2% over 52 weeks. Its 52-week range is 2.770 USD to 12.47 USD: the price is 77.5% below the high and 1.4% above the low.
Its market capitalisation is 53.03M USD.
Outset Medical reports return on equity of -64.3%, an operating margin of -51.2% and revenue up 14.2% year over year.
It holds more cash than debt, a net cash position of 31.85M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 7.667 USD is 172.8% above the current price. The next earnings report is expected on 10 February 2027.